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Acute lymphoblastic leukemia cells create a
leukemic niche without affecting the
CXCR4/CXCL12 axis
Acute lymphoblastic leukemia (ALL) is characterized by
an outgrowth of malignant lymphoblasts that occupy the
bone marrow microenvironment where they reside with
mesenchymal stromal cells (MSCs).1 Leukemic cells are able
to disrupt the healthy microenvironment and create a
leukemic niche that shelters malignant cells from elimina-
tion through cytostatic treatment and immune responses.2,3
Disrupting intercellular communication in this malignant
microenvironment sensitizes leukemic cells to chemother-
apeutic drugs.4  Homing of ALL cells toward the bone mar-
row microenvironment is thought to be similar to that of
hematopoietic stem cells (HSCs).5 Human CD34+ progeni-
tor cells, are attracted by stromal cell-derived factor 1 (SDF-
1/CXCL12), a chemoattractant actively produced by MSCs
in the bone marrow.5,6 CXCL12 binds to the CXCR4 recep-
tor. Disturbance of the CXCR4/CXCL12 axis by treatment
with cytokines and/or CXCR4 antagonists mobilizes HSCs
to the peripheral blood7 and shows promising pre-clinical
results in acute myeloid leukemia patients.8 Like HSCs, ALL
cells have high CXCR4 surface expression and disruption
of CXCR4/CXCL12 interaction reduces ALL engraftment
in animal models.9,10 However, in mice suffering from ALL,
CXCR4/CXCL12 inhibition as mono-treatment did not
reduce the leukemic cell number in the bone marrow.9,11 In
addition, CXCL12 expression was remarkably down-regu-
lated in murine bone marrow regions of extensive ALL
growth.1 Likewise, CXCL12 levels in the bone marrow of
patients diagnosed with BCP-ALL were lower compared to
those in the same patients at the time of remission and
healthy controls.6 This suggests that ALL cells use addition-
al mechanisms to retain a protective microenvironment.
In this study, we used an ex vivo co-culture model in
which we cultured B-cell precursor ALL (BCP-ALL) cells
with bone marrow-derived primary MSCs. Several studies
show that ALL cells home toward the bone marrow
microenvironment in a CXCR4/CXCL12-dependent man-
ner.1,9,10 We confirmed these findings in our model by assess-
ing the migration of GFP-positive BCP-ALL cells (NALM6)
toward MSCs using a transwell system. MSCs induced
migration of BCP-ALL cells by 5-16-fold compared to medi-
um controls (P<0.05) (Figure 1A and Online Supplementary
Figure S1A and B). The induction of migration was correlat-
ed with the level of CXCL12 produced by the primary
MSCs (Figure 1B). Inhibition of the CXCR4/CXCL12 axis
with AMD3100 significantly impaired migration of BCP-
ALL cells toward MSCs (4.5-fold reduction; P<0.01) (Figure
1C).
Next, we hypothesized that BCP-ALL cells alter the
chemoattractive properties of their microenvironment. To
address this hypothesis, GFP-negative BCP-ALL cells
(NALM6) were cultured with MSCs in the bottom com-
partment of a transwell system as a model of the leukemic
niche. Migration of GFP-positive BCP-ALL cells (NALM6)
from the upper to the bottom compartment was deter-
mined (Online Supplementary Figure S1A-C). GFP-positive
BCP-ALL cells migrated significantly more toward ALL-
MSC co-cultures than toward MSCs in mono-culture (blue
bars vs. gray bars; P<0.01) (Figure 1D and Online
Supplementary Figure S1D and E). The leukemic niche
induced migration of BCP-ALL cells by 2.2-fold (P<0.001)
(Figure 1E). Surprisingly, CXCR4 inhibition by AMD3100
did not affect the preferential migration of BCP-ALL cells
towards the leukemic niche (2.2-fold vs. 2.5-fold; P=0.52)
(Figure 1E and Online Supplementary Figure S1F). In addi-
tion, we compared CXCL12 levels in the supernatant of
mono- and co-cultures of primary BCP-ALL cells derived
from 9 different BCP-ALL cases and 4 primary MSCs.
CXCL12 levels were high in mono-cultures of MSCs, and
below detection level in mono-cultures of primary BCP-
ALL cells (Online Supplementary Figure S2A and B). Co-cul-
ture of primary BCP-ALL cells and MSCs did not increase
CXCL12 levels compared to the combined levels produced
in both mono-cultures (Figure 1F). These results suggest
that BCP-ALL cells create a leukemic niche that attracts
leukemic cells in a CXCR4/CXCL12-independent manner. 
Next, we assessed the migration of healthy CD34+
hematopoietic progenitor cells (HPCs) toward primary
MSCs cultured with or without BCP-ALL cells. As expect-
ed, CD34+ HPCs migrated more abundantly toward MSCs
than to control medium without MSCs (1.8-fold; P<0.05)
(Figure 1G). However, migration of CD34+ HPCs toward
ALL-MSC co-cultures was significantly reduced compared
to migration toward MSCs in mono-cultures (20% reduc-
tion; P<0.05) (Figure 1G). In addition, we assessed the
migratory behavior of healthy MSCs toward ALL-MSC co-
cultures. We performed a transwell migration assay in
which primary MSCs were allowed to migrate toward
BCP-ALL cells or other MSCs in the bottom compartment.
We observed that MSC migration was induced toward
other MSCs compared to control medium (P<0.05) 
(Figure 1H). Strikingly, MSCs also actively migrated to BCP-
ALL cells illustrating that BCP-ALL cells are able to recruit
MSCs (P<0.001) (Figure1H and Online Supplementary Figure
S3A). However, MSC migration was significantly inhibited
toward the leukemic niche (ALL-MSC co-cultures) com-
pared to a bottom compartment containing only BCP-ALL
cells (2-3-fold reduction; P<0.001) (Figure 1I and Online
Supplementary Figure S3B and C). Interestingly, increasing
the amount of ALL cells (up to 16-fold) in ALL-MSC co-cul-
tures did not re-induce MSC migration (Figure 1I). These
results show that ALL-MSC co-cultures efficiently attract
leukemic cells, but reduce migration of healthy CD34+
HPCs and primary MSCs, suggesting that ALL-MSC co-cul-
tures produce chemokines that specifically attract BCP-ALL
cells. 
To address which cytokines/chemokines may be altered
in the leukemic niche, we quantified the levels of 64
cytokines known to be important in immunology/hematol-
ogy in the supernatant of ex vivo co-cultures of patient-
derived BCP-ALL cells (n=10, representing major BCP-ALL
subgroups) and MSCs (n=4) (Online Supplementary Table
S1). Cytokine/chemokine profiles of mono-cultures of pri-
mary BCP-ALL cells and primary MSCs are shown in
Online Supplementary Figure S2. Co-cultures of BCP-ALL
cells with MSCs revealed the induction of unique secretion
patterns per patient. These patterns were similar for differ-
ent sources of MSC, i.e. MSCs obtained at the time of
leukemia and those obtained from healthy controls.  The
unique profile per BCP-ALL patients suggests that leukemic
cells govern the observed cytokine secretion (Figure 2,
Online Supplementary Table S2 and Online Supplementary
Figure S4A and B). These unique cytokine/chemokine pro-
files suggest the need for patient-specific approaches to dis-
rupt the leukemic niche. However, we also found recur-
rently induced signaling pathways. All ALL-MSC co-cul-
tures showed increased levels of CCL2/MCP-1 and/or
CCL22/MDC (Figure 2A), both ligands for the CCR4 recep-
tor. This chemokine receptor is implicated in T-cell
leukemia and lymphoma, but has not yet been implicated
as an important factor in BCP-ALL.12  In addition, analysis of
previously published microarray-based gene expression
data showed that CCR4 expression levels in pediatric ALL
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cells were significantly higher compared to healthy
hematopoietic cells (Online Supplementary Figure S4C).
In addition, we observed recurrent induction of
CXCL8/IL-8 and CXCL1/GRO secretion, ligands of the
CXCR1 and CXCR2 receptor. CXCR1/2 ligands were
induced by BCP-ALL cells from 6 out of 10 patients 
(Figure 2C). In contrast to CCR4 expression, CXCR1 and
CXCR2 expression levels were lower in pediatric ALL com-
pared to healthy hematopoietic cells (Online Supplementary
Figure S3C). 
We validated the cytokine/chemokine patterns identified
in our co-culture model using serum derived from bone
marrow aspirates from 10 ALL patients at diagnosis. We
compared the cytokine/chemokine patterns in these sam-
ples with serum obtained from bone marrow aspirates of
the same patients taken at the end of induction chemother-
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(E) Graph showing that the leukemic niche affects the migration of BCP-ALL cells independent of CXCR4/CXCL12 signaling. Migration of NALM6 cells toward
NALM6-MSC co-cultures (leukemic niche, blue bars) is compared to migration toward MSC mono-cultures (normal niche, gray bars) in absence or presence of
AMD3100 (10 µM) after 48 h using a 3.0 µm transwell system (n=4; one-tailed t-test, paired). For this experiment, we combined the data of four distinct primary
MSCs (MSC#1-4). Data are shown as fold-induction compared to migration towards MSC mono-culture. (F) Plots show the secreted levels of CXCL12 by primary
BCP-ALL cells and MSCs in mono-culture (circles represent the sum of cytokine secretion in mono-culture of BCP-ALL and mono-culture of MSC) compared to
ALL-MSC co-culture (squares). Data were determined using a multiplexed fluorescent bead-based immunoassay. Boxes represent p25-p75 intervals. (G) Graph
showing the migration of umbilical cord blood-derived healthy CD34+ progenitor cells after 48 h in a 3.0 μm transwell system. Bars represent migration toward
culture medium, NALM6 cells, MSCs and NALM6-MSC cultures (n=3; one-tailed t-test; paired). Migration towards MSC mono-culture was used to calculate the
fold-change migration. Data are mean±Standard Error of Mean (SEM); *P≤0.05. (H and I) Primary MSCs (experiments performed with MSC#1 and MSC#3) were
allowed to migrate to the other side of a 8.0 µm transwell insert for 16 h. Cells were fixed and subsequently stained with crystal violet. MSCs migrated toward
a bottom compartment containing culture medium, MSCs or BCP-ALL cells (REH). The amount of migrated cells was measured by spectrophotometry of crystal
violet stained cells. (H) Graph showing the migration of primary MSCs. Migration towards medium was used to calculate the fold-change migration (n=4; one-
tailed t-test; paired). (I) Graph showing the migration of primary MSCs toward REH cells (BCP-ALL, black bars) or REH-MSC co-cultures (leukemic niche, blue
bars) (n=4; one-tailed t-test, paired). Data are relative to control condition without BCP-ALL cells (medium-only or MSC-only control). Data are expressed as
mean±SEM; *P≤0.05, **P≤0.01, ***P≤0.001. See also Online Supplementary Figures S1-S3. N6: NALM6; HPC: hematopoietic progenitor cell.
Figure 1. Acute lymphoblastic
leukemia (ALL) mesenchymal stro-
mal cell (MSC) co-cultures induce
leukemic cell migration without
affecting the CXCR4/CXCL12 axis.
(A) Fold-change in migration of GFP-
positive B-cell precursor (BCP)-ALL
cells (NALM6) toward four distinct pri-
mary bone marrow-derived MSCs
compared to background migration
toward culture medium after 48
hours (h) in a 3.0 µm transwell sys-
tem (n=5 for each MSC; one-tailed 
t-test, unpaired). We used MSCs
derived from healthy controls (MSC#1
and MSC#2) and MSCs derived from
leukemia patients at diagnosis
(MSC#3 and MSC#4); see also Online
Supplementary Table S3. Migration
towards culture medium was used to
calculate the fold-change migration.
(B) Graph showing the secretion of
CXCL12 by primary MSCs as deter-
mined using a fluorescent bead-
based immunoassay (n=6 for each
MSC). (C) Graph showing the effect of
CXCR4 blockade with AMD3100 
(10 µM) on the migration of NALM6
cells toward primary MSCs after 48 h
in a 3.0 µm transwell system (n=4;
one-tailed t-test, paired). Migration
towards culture medium was used to
calculate the fold-change migration.
For this experiment, we combined the
data of four distinct primary MSCs
(MSC#1-4). (D) Migration of NALM6
cells toward MSCs in mono-culture
(normal niche, gray bars) or toward
ALL-MSC co-cultures (leukemic niche,
blue bars) after 48 h in a 3.0 µm tran-
swell system (n=5 for each MSC; one-
tailed t-test, paired). Migration
towards culture medium was used to
calculate the fold-change migration.
Experiments were performed with
MSCs from 4 donors. 
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Figure 2. Chemokines inducing the CCR4 and CXCR1/2 axes are up-regulated in the B-cell precursor (BCP)-acute lymphoblastic leukemia (ALL) niche. (A)
Plots showing the secretion of CCL2/MCP-1 and CCL22/MDC by primary mesenchymal stromal cells (MSCs) (n=4) and primary BCP-ALL cells (n=10) in mono-
culture (circles represent the sum of cytokine secretion in mono-culture of BCP-ALL and mono-culture of MSC) compared to ALL-MSC co-cultures (squares). Data
were obtained using a multiplexed fluorescent bead-based immunoassay. Boxes represent p25-p75 intervals. Raw data were logarithmically transformed to
obtain a normal distribution of the data and upregulation of cytokines was tested using a one-tailed paired t-test; *P≤0.05, **P≤0.01, ***P≤0.001. (B) Plots
showing the serum levels of CCL2/MCP-1 and CCL22/MDC in bone marrow aspirates from healthy controls (n=7, circles), from untreated BCP-ALL patients at
diagnosis (n=10, blue squares) and from BCP-ALL patients after induction treatment (n=10, triangles; lines indicate paired samples). Data were obtained using
a multiplexed fluorescent bead-based immunoassay in which we measured the levels of 64 cytokines. Healthy (circles) and leukemic samples (blue squares)
were compared using a two-tailed unpaired t-test. Leukemic samples before and after induction therapy (blue squares vs. triangles) were compared using a
one-tailed paired t-test; *P≤0.05, **P≤0.01, ***P≤0.001. (C) Same as (A) for CXCL8/IL-8 and CXCL1/GRO secretion. (D) Plots showing the serum levels of
GRO/CXCL1 and CXCL8/IL-8. See also Online Supplementary Tables S1 and S2, and Online Supplementary Figures S2 and S4. 
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apy. At this stage of treatment, the patients were in remis-
sion. Furthermore, we used bone marrow aspirates of 7
healthy controls to analyze cytokine/chemokine patterns
of the healthy niche. Levels of the CCR4 ligand
CCL2/MCP-1 were significantly higher in the bone mar-
row of untreated, newly diagnosed BCP-ALL patients com-
pared to healthy controls (2.0-fold increase; P<0.01) 
(Figure 2B). Interestingly, after induction therapy, the
CCL2/MCP-1 levels in the bone marrow of ALL patients
decreased to levels observed in healthy controls (2.2-fold
decrease; P<0.01) (Figure 2B). This suggests that the
induced CCL2/MCP-1 levels at diagnosis are causally
linked to the presence of leukemic cells. CCL22/MDC lev-
els were similar between BCP-ALL patients and healthy
controls (Figure 2B). Like CCL2/MCP-1, CXCL1/GRO lev-
els were also increased in the bone marrow of BCP-ALL
patients (2.3-fold increase; P<0.05) (Figure 2D) and
CXCL8/IL8 levels showed a trend towards upregulation
(2.5-fold; P=0.052) (Figure 2D). Similar to CCL2/MCP-1
levels, the secreted levels of these CXCR1/2 ligands were
significantly reduced after induction chemotherapy (2.3-
fold and 3.1-fold, respectively; P<0.05) (Figure 2D). These
data implicate that CCR4 and CXCR1/2 signaling are
important in the bone marrow of BCP-ALL patients and
suggest that CCR4 inhibition (e.g. by mogamulizumab1)13
or CXCR1/2 inhibition might be an alternative or addition-
al way to disrupt the BCP-ALL niche.
In conclusion, our data indicate that the BCP-ALL niche
is highly potent in attracting BCP-ALL cells and repelling
the influx of healthy hematopoietic cells and MSCs in a
CXCL12-independent manner. Instead, we show the recur-
rent induction of CCR4 and CXCR1/2 ligands by BCP-ALL
cells in the leukemic niche (Figure 3). Our data suggest
CCR4 and CXCR1/2 to be valuable future therapeutic tar-
gets to interfere with the leukemic niche in ALL.
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